Insider Buying: BlossomHill Therapeutics (NASDAQ:BLSM) Director Acquires $96,000.00 in Stock

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Director John Schmid bought 6,000 shares of the stock in a transaction dated Monday, August 10th. The shares were purchased at an average price of $16.00 per share, with a total value of $96,000.00. Following the completion of the transaction, the director directly owned 6,000 shares in the company, valued at approximately $96,000. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

BlossomHill Therapeutics Price Performance

BLSM stock opened at $16.24 on Thursday. BlossomHill Therapeutics, Inc. has a fifty-two week low of $15.25 and a fifty-two week high of $17.25.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.